Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Objective To determine the effects of volanesorsen (ISIS 304801), a second-generation 2'-O-methoxyethyl chimeric antisense inhibitor of apolipoprotein (apo)C-III, on triglyceride (TG) levels and insulin resistance in patients with type 2 diabetes. Research design and methods A randomized, double-blind, placebo-controlled trial was performed in 15 adult patients with type 2 diabetes (HbA1c >7.5% [58 mmol/mol]) and hypertriglyceridemia (TG >200 and Results Treatment with volanesorsen significantly reduced plasma apoC-III (-88%, P = 0.02) and TG (-69%, P = 0.02) levels and raised HDL cholesterol (HDL-C) (42%, P = 0.03) compared with placebo. These changes were accompanied by a 57% improvement in whole-body insulin sensitivity (P Conclusions Volanesorsen reduced plasma apoC-III and TG while raising HDL-C levels. Importantly, glucose disposal, insulin sensitivity, and integrative markers of diabetes also improved in these patients after short-term treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The COMPASS trial, which evaluated volanesorsen in patients with multifactorial chylomicronemia (with partial LPL activity), similarly demonstrated substantial TG reductions (~ 71%) and improved metabolic parameters, broadening the potential utility of apoC-III inhibition beyond the rare FCS population.”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [47]
In the citing paper
“In addition to TG lowering, volanesorsen has been shown to reduce apoC-III by ~ 80–88% and increase HDL-C by ~ 42% compared with placebo [45–47].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [47]
In the citing paper
“This correlated with >80% reductions in apo C-III, favourable changes across multiple lipoprotein species, unchanged LDL-C and improved carbohydrate metabolism.69–71”
From Clinical review on triglycerides (2020) · cites this paper as [70]
In the citing paper
“In the liver, nicotinic acid inhibits diacylglycerol acyltransferase2 resulting in decreased secretion of VLDL particles, which is also reflected in reductions of plasma levels of both IDL and LDL particles [335].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [335]
In the citing paper
“Nicotinic acid primarily raises HDL-C and ApoA1 by stimulating ApoA1 production in the liver [335].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [335]
Citations
Cites
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Cellular mechanisms of insulin resistance
Shulman, G. I. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10583 · Cited by 2,714
Muniyappa, R., Lee, S., Chen, H., & Quon, M. J. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00645.2007 · Cited by 1,643
Insulin resistance and cardiovascular disease
Ginsberg, H. N. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10762 · Cited by 1,358
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919 · cited 1×
“Two recent Mendelian randomization studies showed that individuals with loss-of-function APOC3 variants had lower TG concentrations and LDL-C, higher HDL-C, and, compellingly, a 40% reduction in risk of coronary heart disease (15,16).”
BackgroundESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R. S., Hughes, S. G., Viney, N. J., Graham, M. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1400283 · Cited by 528
Self-citationWu, L., & Parhofer, K. G. (2014) · Metabolism · doi:10.1016/j.metabol.2014.08.010 · Cited by 516
Targeting APOC3 in the familial chylomicronemia syndrome
Gaudet, D., Brisson, D., Tremblay, K., Alexander, V. J., Singleton, W., Hughes, S. G., Geary, R. S., Baker, B. F., Graham, M. J., Crooke, R. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400284 · Cited by 491
Self-citationJacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., McKenney, J. M., Grundy, S. M., Gill, E. A., Wild, R. A., et al. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.07.007 · Cited by 462 · cited 1×
“Because the TG-reducing effect of statins is modest at best, patient-centered guidelines also recommend a second drug such as fibric acid derivatives, niacin, or n-3 fatty acids (3).”
BackgroundApolipoprotein C3 gene variants in nonalcoholic fatty liver disease
Petersen, K. F., Dufour, S., Hariri, A., Nelson-Williams, C., Foo, J. N., Zhang, X.-M., Dziura, J., Lifton, R. P., & Shulman, G. I. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907295 · Cited by 428
Heilbronn, L., Smith, S. R., & Ravussin, E. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802853 · Cited by 412 · cited 1×
“Patients with lipodystrophy, unable to store excess calories in adipocytes, develop ectopic lipid deposits in muscle and liver, which lead to an increase flux of free fatty acids and severe insulin resistance (39).”
BackgroundGraham, M. J., Lee, R. G., Bell, T. A., Fu, W., Mullick, A. E., Alexander, V. J., Singleton, W., Viney, N., Geary, R., Su, J., et al. (2013) · Circulation Research · doi:10.1161/circresaha.111.300367 · Cited by 377 · cited 4×
“Recapitulating preclinical models, treating normolipidemic and hypertriglyceridemic human subjects with the human-specific apoC-III ASO, volanesorsen (ISIS 304801), profoundly reduced plasma apoC-III protein and plasma TG levels (18,19).”
BackgroundMethodInfluentialSelf-citationFoxo1 mediates insulin action on apoC-III and triglyceride metabolism
Altomonte, J., Lin, C., Harbaran, S., Richter, A. M., Xu, J., Meseck, M. L., & Dong, H. H. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19992 · Cited by 309
Apolipoprotein C-III: understanding an emerging cardiovascular risk factor
Ooi, E. M. M., Barrett, P. H. R., Chan, D. C., & Watts, G. F. (2008) · Clinical Science · doi:10.1042/cs20070308 · Cited by 282 · cited 8×
“This latter study demonstrates that apoC-III also inhibits an LPL-independent pathway of TRL clearance.”
BackgroundInfluentialFoxo1 mediates insulin action on apoC-III and triglyceride metabolism
Altomonte, J., Lin, C., Harbaran, S., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200419992 · Cited by 260
The Insulin Resistance Syndrome: Impact on Lipoprotein Metabolism and Atherothrombosis
Ginsberg, H. N., & Huang, L.-S. (2000) · European Journal of Cardiovascular Risk · doi:10.1177/204748730000700505 · Cited by 209 · cited 1×
“While it is well established that insulin resistance drives dyslipidemia, there is growing evidence that the elevation in plasma TGs and reduction in HDL-C accompanying insulin resistance states may exacerbate the insulin-resistant phenotype, albeit by yet-to-be-defined mechanisms (7).”
BackgroundBruckert, E., Labreuche, J., Deplanque, D., Touboul, P.-J., & Amarenco, P. (2011) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318202709f · Cited by 192 · cited 1×
“In support of this approach, meta-analyses of five large trials assessing the impact of fibrates on cardiovascular end points revealed benefits among patients with the lipid triad (6).”
ResultApolipoprotein C-II and C-III levels in hyperlipoproteinemia
Schonfeld, G., George, P. K., Miller, J., Reilly, P., & Witztum, J. (1979) · Metabolism · doi:10.1016/0026-0495(79)90004-0 · Cited by 176
Caron, S., Verrijken, A., Mertens, I., Samanez, C. H., Mautino, G., Haas, J. T., Duran-Sandoval, D., Prawitt, J., Francque, S., Vallez, E., et al. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.220723 · Cited by 162
Fructosamine and glycated albumin and the risk of cardiovascular outcomes and death
Selvin, E., Rawlings, A. M., Lutsey, P. L., Maruthur, N., Pankow, J. S., Steffes, M., & Coresh, J. (2015) · Circulation · doi:10.1161/circulationaha.115.015415 · Cited by 151 · cited 1×
“Recent evidence indicates that, like HbA1c, the medium-term markers also associate with cardiovascular risk (30,31).”
Backgroundvon Eckardstein, A., & Sibler, R. A. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283412279 · Cited by 151 · cited 3×
“It is thought that the inability of insulin resistant adipose tissue to store TG may be the initial step in the development of insulin resistance (1,31).”
BackgroundLee, H.-Y., Birkenfeld, A. L., Jornayvaz, F. R., Jurczak, M. J., Kanda, S., Popov, V., Frederick, D. W., Zhang, D., Guigni, B., Bharadwaj, K. G., et al. (2011) · Hepatology · doi:10.1002/hep.24571 · Cited by 134 · cited 2×
“Mice overexpressing apoC-III not only have high plasma TG but also display increased insulin resistance (12).”
BackgroundThe Clinical Approach to the Detection of Lipodystrophy an Aace Consensus Statement
Handelsman, Y., Oral, E. A., Bloomgarden, Z. T., Brown, R. J., Chan, J. L., Einhorn, D., Garber, A. J., Garg, A., Timothy Garvey, W., Grunberger, G., et al. (2013) · Endocrine Practice · doi:10.4158/endp.19.1.v767575m65p5mr06 · Cited by 125
Markers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity
Chan, D. C., Watts, G. F., Barrett, P. H., Mamo, J. C., & Redgrave, T. G. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.2.278 · Cited by 117
Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects.
Batal, R., Tremblay, M., Barrett, P. H. R., Jacques, H., Fredenrich, A., Mamer, O., Davignon, J., & Cohn, J. S. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32379-8 · Cited by 113
An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor?
Chan, D. C., Chen, M. M., Ooi, E. M. M., & Watts, G. F. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01678.x · Cited by 85 · cited 9×
“This latter study demonstrates that apoC-III also inhibits an LPL-independent pathway of TRL clearance.”
BackgroundInfluentialHDLs Protect Pancreatic β-Cells Against ER Stress by Restoring Protein Folding and Trafficking
Pétremand, J., Puyal, J., Chatton, J., Duprez, J., Allagnat, F., Frias, M. A., James, R. W., Waeber, G., Jonas, J., & Widmann, C. (2012) · Diabetes · doi:10.2337/db11-1221 · Cited by 83 · cited 1×
“In preclinical models, HDL may improve insulin sensitivity, insulin secretion through the b-cells, and b-cell survival (8).”
Qamar, A., Khetarpal, S. A., Khera, A. V., Qasim, A., Rader, D. J., & Reilly, M. P. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.305415 · Cited by 76
Verrijken, A., Beckers, S., Francque, S., Hilden, H., Caron, S., Zegers, D., Ruppert, M., Hubens, G., Van Marck, E., Michielsen, P., et al. (2013) · Obesity · doi:10.1002/oby.20366 · Cited by 65 · cited 1×
“However, in more recent studies, it does not appear that apoC-III is directly associated with the incidence of nonalcoholic fatty liver disease in broader patient populations (14).”
BackgroundLowering apolipoprotein CIII delays onset of type 1 diabetes
Holmberg, R., Refai, E., Höög, A., Crooke, R. M., Graham, M., Olivecrona, G., Berggren, P.-O., & Juntti-Berggren, L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019553108 · Cited by 59
Self-citationFlorez, H. J., Mendez, A. J., Casanova-Romero, P. Y., Larreal, C., Castillo-Florez, S., Lee, D. J., & Goldberg, R. B. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.10.013 · Cited by 48
Pedrini, M. T., Niederwanger, A., Kranebitter, M., Tautermann, C. S., Ciardi, C., Tatarczyk, T., & Patsch, J. R. (2006) · Diabetologia · doi:10.1007/s00125-006-0262-z · Cited by 46 · cited 1×
“Clinical experiments have shown that excessive plasma NEFAs are not required for hypertriglyceridemia to provoke insulin resistance (33), and suppressing NEFA does not reverse insulin resistance when intracellular fatty acids remain elevated (34).”
BackgroundAPOC3, Coronary Disease, and Complexities of Mendelian Randomization
Cohen, J. C., Stender, S., & Hobbs, H. H. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.08.007 · Cited by 46 · cited 1×
“While it is unclear whether the coronary heart disease risk reduction is due to suppressed TG, other TRLassociated factors, or apoC-III per se, the aforementioned cardioprotective properties suggest that apoC-III is an attractive therapeutic target (17).”
BackgroundSusceptibility to Type 1 Diabetes Is Associated With ApoCIII Gene Haplotypes
Hokanson, J. E., Kinney, G. L., Cheng, S., Erlich, H. A., Kretowski, A. J., & Rewers, M. (2006) · Diabetes · doi:10.2337/diabetes.55.03.06.db05-1380 · Cited by 36
Identification of ApoB-Containing Lipoprotein Families in NIDDM
Alaupovic, P., Bard, J.-M., Tavella, M., & Shafer, D. (1992) · Diabetes · doi:10.2337/diab.41.2.s18 · Cited by 33
Kassai, A., Muniyappa, R., Levenson, A. E., Walter, M. F., Abel, B. S., Ring, M., Taylor, S. I., Biddinger, S. B., Skarulis, M. C., Görden, P., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3891 · Cited by 15 · cited 2×
“A recent study showed that elevated apoC-III is associated with the hypertriglyceridemia seen in both generalized and partial lipodystrophy, suggesting that apoC-III may represent a therapeutic target in these patients (38).”
BackgroundPlasma Apolipoprotein C-III Levels in Children With Type I Diabetes
Blackett, P. R., Sarale, D. C., Fesmire, J. D., Harmon, J. P., WEECH, P. K., & Alaupovic, P. (1988) · Southern Medical Journal · doi:10.1097/00007611-198804000-00015 · Cited by 12
Johnson, N. A., Stannard, S. R., ROWLANDS, D. S., Chapman, P., Thompson, C. H., Sachinwalla, T., & Thompson, M. W. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01952.x · Cited by 7 · cited 1×
“Clinical experiments have shown that excessive plasma NEFAs are not required for hypertriglyceridemia to provoke insulin resistance (33), and suppressing NEFA does not reverse insulin resistance when intracellular fatty acids remain elevated (34).”
BackgroundMethods for Quantifying Insulin Sensitivity and Determining Insulin Time-Action Profiles
Krentz, A. J., Heinemann, L., & Hompesch, M. (2014) · Springer eBooks · doi:10.1007/978-1-4471-4920-0_1 · Cited by 6 · cited 1×
“, Indianapolis, IN) was infused using a precision pump at a rate calculated to acutely elevate serum insulin concentration from basal (fasting) levels to predefined plateaus (21,22).”
MethodSelf-citation
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
“On the other, agents that enhance catabolism of TG-rich lipoproteins, such as the antisense oligonucleotide to ApoC-III, and which lead to a concomitant reduction in TGs ( 70%) and a marked elevation in HDL-C ( 40%) in hypertriglyceridemia, are under development.(351) Importantly, however, we currently lack understand…”
Crooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.004 · Cited by 841
Self-citationAntisense technology: an overview and prospectus
Crooke, S. T., Baker, B. F., Crooke, R. M., & Liang, X.-H. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00162-z · Cited by 775
Self-citationChemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs
Shen, X., & Corey, D. R. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1239 · Cited by 632
“Clinical trials have revealed decreased ApoC-III levels, reducing cardiovascular risk and improving insulin sensitivity (141,142).”
Background
Metadata
- Authors
- Digenio, A., Dunbar, R. L., Alexander, V. J., Hompesch, M., Morrow, L., Lee, R. G., Graham, M. J., Hughes, S. G., Yu, R., Singleton, W., Baker, B. F., Bhanot, S., & Crooke, R. M.
- Affiliations
- Akcea Therapeutics, Cambridge, MA
- University of Pennsylvania (US)
- Ionis Pharmaceuticals (United States) (US)
- Profil Institute for Clinical Research (US)
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-06-06
- Volume
- 39
- Issue
- 8
- Pages
- 1408-1415
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2418001336
- Cited by
- 170
- References
- 41
- Citations by year
- 2026: 8 · 2025: 17 · 2024: 16 · 2023: 16 · 2022: 18 · 2021: 18 · 2020: 19 · 2019: 23 · 2018: 13 · 2017: 14 · 2016: 7
- FWCI
- 15.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- volanesorsen, apolipoprotein C-III, antisense oligonucleotides, type 2 diabetes, hypertriglyceridemia, insulin sensitivity, insulin resistance, triglycerides, HDL cholesterol, glycated albumin, fructosamine, glycemic control, glucose disposal
- MeSH terms
- Aged, Anticholesteremic Agents, Blood Glucose, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Female, Glycated Hemoglobin, Humans, Insulin Resistance, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Triglycerides, Hypertriglyceridemia, Biomarkers, Oligonucleotides, Antisense, Apolipoprotein C-III
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.